Jaguar Health Submitted an IND Application to the US FDA for NP-300 to Treat Cholera-Related Diarrhea
- Jaguar Health’s Napo submitted the IND for NP-300 for the symptomatic treatment & relief from infectious diarrhea from pathogens. The company has also received partial financial support for IND enabling preclinical toxicity studies by the NIAID
- The company intends to receive a TDPRV for the development of NP-300 for the same indication. Jaguar entered into a $6M financing agreement with Streeterville Capital, under which Streeterville received the right to 18% of the gross proceeds from the sale of TDPRV
- Jaguar expects to initiate the P-I clinical trial evaluating NP-300 for the treatment of cholera-related diarrhea by Sep 30, 2022. NP-300 is an oral botanical drug sustainably derived from the Croton lechleri tree
Ref: Accesswire | Image: Jaguar Health
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.